TY - JOUR
T1 - A Case of Chronic Lymphocytic Leukemia Complicated by Hemophagocytic Lymphohistiocytosis
T2 - Identifying the Aberrant Immune Response
AU - Zoref-Lorenz, Adi
AU - Yuklea, Mona
AU - Topaz, Guy
AU - Jordan, Michael B.
AU - Ellis, Martin
N1 - Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Society of General Internal Medicine.
PY - 2022/5
Y1 - 2022/5
N2 - Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that may complicate hematologic malignancies. HLH and malignancies have common clinical features, and HLH diagnostic criteria (HLH-2004/Hscore) were not validated in this specific population. We describe a case of a 72-year-old patient with a history of chronic lymphocytic leukemia stable for over 10 years who presented with fever and cytopenia. After excluding infectious etiologies and the progression of her disease, HLH was diagnosed. The patient was treated with etoposide, dexamethasone, intravenous immunoglobulin, and rituximab. Despite initial clinical improvement, the patient deteriorated and developed pulmonary aspergillosis and CNS involvement that reflected uncontrolled HLH. The patient died 45 days after her presentation. An unusual feature of this case was that HLH was not triggered by infection, disease transformation, or treatment. This case emphasizes the challenges of differentiating the development of overwhelming HLH from other complications associated with hematologic malignancy.
AB - Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that may complicate hematologic malignancies. HLH and malignancies have common clinical features, and HLH diagnostic criteria (HLH-2004/Hscore) were not validated in this specific population. We describe a case of a 72-year-old patient with a history of chronic lymphocytic leukemia stable for over 10 years who presented with fever and cytopenia. After excluding infectious etiologies and the progression of her disease, HLH was diagnosed. The patient was treated with etoposide, dexamethasone, intravenous immunoglobulin, and rituximab. Despite initial clinical improvement, the patient deteriorated and developed pulmonary aspergillosis and CNS involvement that reflected uncontrolled HLH. The patient died 45 days after her presentation. An unusual feature of this case was that HLH was not triggered by infection, disease transformation, or treatment. This case emphasizes the challenges of differentiating the development of overwhelming HLH from other complications associated with hematologic malignancy.
KW - CLL
KW - HLH
KW - chronic lymphocytic leukemia
KW - fever
KW - hemophagocytic lymphohistiocytosis
KW - hemophagocytic syndrome
KW - pancytopenia
UR - http://www.scopus.com/inward/record.url?scp=85125094254&partnerID=8YFLogxK
U2 - 10.1007/s11606-022-07395-7
DO - 10.1007/s11606-022-07395-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35178648
AN - SCOPUS:85125094254
SN - 0884-8734
VL - 37
SP - 1542
EP - 1546
JO - Journal of General Internal Medicine
JF - Journal of General Internal Medicine
IS - 6
ER -